Laura Chico
Stock Analyst at Wedbush
(3.58)
# 839
Out of 5,148 analysts
237
Total ratings
47.53%
Success rate
6.38%
Average return
Main Sectors:
Stocks Rated by Laura Chico
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LRMR Larimar Therapeutics | Reiterates: Outperform | $11 | $5.31 | +107.16% | 4 | Feb 25, 2026 | |
| APLS Apellis Pharmaceuticals | Maintains: Neutral | $20 → $18 | $20.13 | -10.58% | 15 | Feb 25, 2026 | |
| GOSS Gossamer Bio | Downgrades: Neutral | $6 → $1 | $0.44 | +128.21% | 7 | Feb 24, 2026 | |
| ARDX Ardelyx | Reiterates: Outperform | $19 | $6.17 | +208.19% | 16 | Feb 23, 2026 | |
| PRAX Praxis Precision Medicines | Maintains: Underperform | $95 → $130 | $318.92 | -59.24% | 12 | Feb 20, 2026 | |
| RARE Ultragenyx Pharmaceutical | Reiterates: Neutral | $25 | $21.96 | +13.84% | 15 | Feb 17, 2026 | |
| NBIX Neurocrine Biosciences | Maintains: Outperform | $149 → $151 | $128.80 | +17.24% | 11 | Feb 12, 2026 | |
| DNTH Dianthus Therapeutics | Maintains: Outperform | $46 → $55 | $54.35 | +1.20% | 12 | Feb 11, 2026 | |
| BIIB Biogen | Maintains: Neutral | $178 → $187 | $183.05 | +2.16% | 20 | Feb 10, 2026 | |
| STOK Stoke Therapeutics | Maintains: Outperform | $32 → $36 | $33.87 | +6.30% | 9 | Jan 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $30 | $19.90 | +50.75% | 10 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $23 → $33 | $39.38 | -16.20% | 9 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $42 → $47 | $28.50 | +64.91% | 8 | Dec 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $30 | $26.50 | +13.23% | 8 | Nov 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $35 → $36 | $44.06 | -18.29% | 2 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $35 → $32 | $28.50 | +12.28% | 11 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $8 | $6.13 | +30.61% | 12 | Sep 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $18 | $13.62 | +32.16% | 3 | Aug 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $14 | $5.92 | +136.49% | 3 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $42 → $43 | $42.14 | +2.04% | 9 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $32 | $28.27 | +13.19% | 12 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $18 | $8.56 | +110.40% | 1 | Jun 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $4 | $18.79 | -78.72% | 4 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $3 | $1.60 | +87.50% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $8 → $7 | $3.97 | +76.54% | 4 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $104 → $88 | $10.85 | +711.06% | 4 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $10.01 | -50.02% | 5 | Mar 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $58.75 | - | 5 | Sep 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $5 | $4.51 | +10.86% | 2 | Aug 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $149 | $10.80 | +1,275.00% | 1 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $720 | $8.01 | +8,888.76% | 1 | Jan 19, 2018 |
Larimar Therapeutics
Feb 25, 2026
Reiterates: Outperform
Price Target: $11
Current: $5.31
Upside: +107.16%
Apellis Pharmaceuticals
Feb 25, 2026
Maintains: Neutral
Price Target: $20 → $18
Current: $20.13
Upside: -10.58%
Gossamer Bio
Feb 24, 2026
Downgrades: Neutral
Price Target: $6 → $1
Current: $0.44
Upside: +128.21%
Ardelyx
Feb 23, 2026
Reiterates: Outperform
Price Target: $19
Current: $6.17
Upside: +208.19%
Praxis Precision Medicines
Feb 20, 2026
Maintains: Underperform
Price Target: $95 → $130
Current: $318.92
Upside: -59.24%
Ultragenyx Pharmaceutical
Feb 17, 2026
Reiterates: Neutral
Price Target: $25
Current: $21.96
Upside: +13.84%
Neurocrine Biosciences
Feb 12, 2026
Maintains: Outperform
Price Target: $149 → $151
Current: $128.80
Upside: +17.24%
Dianthus Therapeutics
Feb 11, 2026
Maintains: Outperform
Price Target: $46 → $55
Current: $54.35
Upside: +1.20%
Biogen
Feb 10, 2026
Maintains: Neutral
Price Target: $178 → $187
Current: $183.05
Upside: +2.16%
Stoke Therapeutics
Jan 12, 2026
Maintains: Outperform
Price Target: $32 → $36
Current: $33.87
Upside: +6.30%
Dec 11, 2025
Maintains: Outperform
Price Target: $31 → $30
Current: $19.90
Upside: +50.75%
Dec 11, 2025
Maintains: Neutral
Price Target: $23 → $33
Current: $39.38
Upside: -16.20%
Dec 10, 2025
Maintains: Outperform
Price Target: $42 → $47
Current: $28.50
Upside: +64.91%
Nov 13, 2025
Maintains: Outperform
Price Target: $27 → $30
Current: $26.50
Upside: +13.23%
Nov 7, 2025
Maintains: Outperform
Price Target: $35 → $36
Current: $44.06
Upside: -18.29%
Nov 7, 2025
Maintains: Outperform
Price Target: $35 → $32
Current: $28.50
Upside: +12.28%
Sep 30, 2025
Maintains: Outperform
Price Target: $9 → $8
Current: $6.13
Upside: +30.61%
Aug 14, 2025
Maintains: Outperform
Price Target: $17 → $18
Current: $13.62
Upside: +32.16%
Aug 13, 2025
Maintains: Outperform
Price Target: $17 → $14
Current: $5.92
Upside: +136.49%
Aug 12, 2025
Maintains: Outperform
Price Target: $42 → $43
Current: $42.14
Upside: +2.04%
Aug 7, 2025
Maintains: Outperform
Price Target: $30 → $32
Current: $28.27
Upside: +13.19%
Jun 30, 2025
Maintains: Outperform
Price Target: $16 → $18
Current: $8.56
Upside: +110.40%
May 15, 2025
Reiterates: Neutral
Price Target: $4
Current: $18.79
Upside: -78.72%
Mar 12, 2025
Maintains: Outperform
Price Target: $4 → $3
Current: $1.60
Upside: +87.50%
Aug 7, 2024
Maintains: Neutral
Price Target: $8 → $7
Current: $3.97
Upside: +76.54%
Apr 11, 2024
Maintains: Outperform
Price Target: $104 → $88
Current: $10.85
Upside: +711.06%
Mar 20, 2024
Reiterates: Neutral
Price Target: $5
Current: $10.01
Upside: -50.02%
Sep 28, 2023
Initiates: Market Perform
Price Target: n/a
Current: $58.75
Upside: -
Aug 12, 2022
Maintains: Outperform
Price Target: $9 → $5
Current: $4.51
Upside: +10.86%
Aug 8, 2022
Downgrades: Neutral
Price Target: $149
Current: $10.80
Upside: +1,275.00%
Jan 19, 2018
Initiates: Outperform
Price Target: $720
Current: $8.01
Upside: +8,888.76%